Antimetastatic effects of razoxane in a rat osteosarcoma model View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

1987-01

AUTHORS

F. Wingen, H. Spring, D. Schmähl

ABSTRACT

The cytostatic and antimetastatic activities of 1,2-di(3,5-dioxopiperazin-1-yl) propane (ICRF-159, razoxane) were studied in a transplantable, slowly growing osteosarcoma in Sprague-Dawley rats. This tumor model is characterized by osteoid formation and spontaneous metastasization to lungs, kidneys and lymph nodes. Razoxane given intraperitoneally (i.p.) from 2 days before to 14 days after tumor transplantation (30 mg/kg or 10 mg/kg per day) resulted in a dose-dependent prolongation of median survival time (83 or 48 days respectively, versus 38 days for the control group), but showed no influence on the growth of the primary tumor.Early treatment with razoxane (30 mg/kg i.p. from day −2 to + 14) showed a greater inhibition of pulmonary metastases than later treatment (30 mg/kg i.p. from day +14 to +28 after transplantation). Whereas 59·9 per cent of the total sectional area of the lungs in the control animals was covered by osteosarcoma metastases, only 3·4 per cent and 26·1 per cent respectively was affected in the early and late razoxane treatment groups. Toxic side-effects of these treatment schedules were reversible diffuse alopecia, but no retardation of body weight gain. More... »

PAGES

9-16

References to SciGraph publications

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/bf00116621

DOI

http://dx.doi.org/10.1007/bf00116621

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1008533853

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/3470164


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Animals", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Bone Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Lung Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoplasm Metastasis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoplasm Transplantation", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Osteosarcoma", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Piperazines", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Prognosis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Rats", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Razoxane", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Institute of Toxicology and Chemotherapy, German Cancer Research Centre, Im Neuenheimer Feld 280, 6900, Heidelberg, F.R. Germany", 
          "id": "http://www.grid.ac/institutes/grid.7497.d", 
          "name": [
            "Institute of Toxicology and Chemotherapy, German Cancer Research Centre, Im Neuenheimer Feld 280, 6900, Heidelberg, F.R. Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Wingen", 
        "givenName": "F.", 
        "id": "sg:person.0763271342.13", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0763271342.13"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Institute of Experimental Pathology, German Cancer Research Centre, Im Neuenheimer Feld 280, 6900, Heidelberg, F.R. Germany", 
          "id": "http://www.grid.ac/institutes/grid.7497.d", 
          "name": [
            "Institute of Experimental Pathology, German Cancer Research Centre, Im Neuenheimer Feld 280, 6900, Heidelberg, F.R. Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Spring", 
        "givenName": "H.", 
        "id": "sg:person.01041422577.30", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01041422577.30"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Institute of Toxicology and Chemotherapy, German Cancer Research Centre, Im Neuenheimer Feld 280, 6900, Heidelberg, F.R. Germany", 
          "id": "http://www.grid.ac/institutes/grid.7497.d", 
          "name": [
            "Institute of Toxicology and Chemotherapy, German Cancer Research Centre, Im Neuenheimer Feld 280, 6900, Heidelberg, F.R. Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Schm\u00e4hl", 
        "givenName": "D.", 
        "id": "sg:person.0105462430.55", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0105462430.55"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1038/222384a0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1049481269", 
          "https://doi.org/10.1038/222384a0"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf00116622", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1039110400", 
          "https://doi.org/10.1007/bf00116622"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf00254053", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013103800", 
          "https://doi.org/10.1007/bf00254053"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "1987-01", 
    "datePublishedReg": "1987-01-01", 
    "description": "The cytostatic and antimetastatic activities of 1,2-di(3,5-dioxopiperazin-1-yl) propane (ICRF-159, razoxane) were studied in a transplantable, slowly growing osteosarcoma in Sprague-Dawley rats. This tumor model is characterized by osteoid formation and spontaneous metastasization to lungs, kidneys and lymph nodes. Razoxane given intraperitoneally (i.p.) from 2 days before to 14 days after tumor transplantation (30 mg/kg or 10 mg/kg per day) resulted in a dose-dependent prolongation of median survival time (83 or 48 days respectively, versus 38 days for the control group), but showed no influence on the growth of the primary tumor.Early treatment with razoxane (30 mg/kg i.p. from day \u22122 to + 14) showed a greater inhibition of pulmonary metastases than later treatment (30 mg/kg i.p. from day +14 to +28 after transplantation). Whereas 59\u00b79 per cent of the total sectional area of the lungs in the control animals was covered by osteosarcoma metastases, only 3\u00b74 per cent and 26\u00b71 per cent respectively was affected in the early and late razoxane treatment groups. Toxic side-effects of these treatment schedules were reversible diffuse alopecia, but no retardation of body weight gain.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/bf00116621", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1094856", 
        "issn": [
          "0262-0898", 
          "1573-7276"
        ], 
        "name": "Clinical & Experimental Metastasis", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "5"
      }
    ], 
    "keywords": [
      "median survival time", 
      "dose-dependent prolongation", 
      "Sprague-Dawley rats", 
      "rat osteosarcoma model", 
      "body weight gain", 
      "pulmonary metastases", 
      "lymph nodes", 
      "tumor transplantation", 
      "primary tumor", 
      "early treatment", 
      "diffuse alopecia", 
      "survival time", 
      "treatment groups", 
      "antimetastatic effect", 
      "control animals", 
      "osteosarcoma metastasis", 
      "osteosarcoma model", 
      "treatment schedule", 
      "late treatment", 
      "antimetastatic activity", 
      "osteoid formation", 
      "tumor model", 
      "weight gain", 
      "razoxane", 
      "total sectional area", 
      "greater inhibition", 
      "metastasis", 
      "lung", 
      "treatment", 
      "days", 
      "cent", 
      "transplantation", 
      "alopecia", 
      "osteosarcoma", 
      "metastasization", 
      "sectional area", 
      "tumors", 
      "rats", 
      "kidney", 
      "prolongation", 
      "inhibition", 
      "transplantable", 
      "animals", 
      "retardation", 
      "group", 
      "schedule", 
      "activity", 
      "effect", 
      "time", 
      "gain", 
      "nodes", 
      "area", 
      "model", 
      "growth", 
      "influence", 
      "formation", 
      "propane"
    ], 
    "name": "Antimetastatic effects of razoxane in a rat osteosarcoma model", 
    "pagination": "9-16", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1008533853"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/bf00116621"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "3470164"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/bf00116621", 
      "https://app.dimensions.ai/details/publication/pub.1008533853"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-12-01T06:19", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221201/entities/gbq_results/article/article_193.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/bf00116621"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/bf00116621'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/bf00116621'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/bf00116621'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/bf00116621'


 

This table displays all metadata directly associated to this object as RDF triples.

186 TRIPLES      21 PREDICATES      96 URIs      85 LITERALS      17 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/bf00116621 schema:about N3b763161c85a4de9a090f180b667c15a
2 N642bdffe351c406c8e932d74157b8984
3 N688293c2cd544b49ac35838b6aff492c
4 N6a4ca3af41f64d55ab1aaea70b393e7b
5 N85603e679821435d8f46ceca4b19bf5a
6 Na0544e204a9249aeb8f87cee54baf279
7 Nc5b735afdd924d58868adf7900d85f3b
8 Ne3cbb97a3aa34424a87312bfb085973d
9 Nf25263e6f345401eae1c16dec74106a5
10 Nf6d6d1c7db7148c9bfde4ec55dcd0dd4
11 anzsrc-for:11
12 anzsrc-for:1103
13 schema:author N954ea1a6ac064151b1b7ba6808ad7fea
14 schema:citation sg:pub.10.1007/bf00116622
15 sg:pub.10.1007/bf00254053
16 sg:pub.10.1038/222384a0
17 schema:datePublished 1987-01
18 schema:datePublishedReg 1987-01-01
19 schema:description The cytostatic and antimetastatic activities of 1,2-di(3,5-dioxopiperazin-1-yl) propane (ICRF-159, razoxane) were studied in a transplantable, slowly growing osteosarcoma in Sprague-Dawley rats. This tumor model is characterized by osteoid formation and spontaneous metastasization to lungs, kidneys and lymph nodes. Razoxane given intraperitoneally (i.p.) from 2 days before to 14 days after tumor transplantation (30 mg/kg or 10 mg/kg per day) resulted in a dose-dependent prolongation of median survival time (83 or 48 days respectively, versus 38 days for the control group), but showed no influence on the growth of the primary tumor.Early treatment with razoxane (30 mg/kg i.p. from day −2 to + 14) showed a greater inhibition of pulmonary metastases than later treatment (30 mg/kg i.p. from day +14 to +28 after transplantation). Whereas 59·9 per cent of the total sectional area of the lungs in the control animals was covered by osteosarcoma metastases, only 3·4 per cent and 26·1 per cent respectively was affected in the early and late razoxane treatment groups. Toxic side-effects of these treatment schedules were reversible diffuse alopecia, but no retardation of body weight gain.
20 schema:genre article
21 schema:isAccessibleForFree false
22 schema:isPartOf N361abf7254d549eb9dcdbb5b44b5ac37
23 N71643238e24d4e89bc14baba149a8c9d
24 sg:journal.1094856
25 schema:keywords Sprague-Dawley rats
26 activity
27 alopecia
28 animals
29 antimetastatic activity
30 antimetastatic effect
31 area
32 body weight gain
33 cent
34 control animals
35 days
36 diffuse alopecia
37 dose-dependent prolongation
38 early treatment
39 effect
40 formation
41 gain
42 greater inhibition
43 group
44 growth
45 influence
46 inhibition
47 kidney
48 late treatment
49 lung
50 lymph nodes
51 median survival time
52 metastasis
53 metastasization
54 model
55 nodes
56 osteoid formation
57 osteosarcoma
58 osteosarcoma metastasis
59 osteosarcoma model
60 primary tumor
61 prolongation
62 propane
63 pulmonary metastases
64 rat osteosarcoma model
65 rats
66 razoxane
67 retardation
68 schedule
69 sectional area
70 survival time
71 time
72 total sectional area
73 transplantable
74 transplantation
75 treatment
76 treatment groups
77 treatment schedule
78 tumor model
79 tumor transplantation
80 tumors
81 weight gain
82 schema:name Antimetastatic effects of razoxane in a rat osteosarcoma model
83 schema:pagination 9-16
84 schema:productId N063c5592b08a4431b5426a4772f2d446
85 N5de6c0fe657441fa8d79a6858129b44a
86 N77bec66543ed40b6a2a096b15ae9eeb0
87 schema:sameAs https://app.dimensions.ai/details/publication/pub.1008533853
88 https://doi.org/10.1007/bf00116621
89 schema:sdDatePublished 2022-12-01T06:19
90 schema:sdLicense https://scigraph.springernature.com/explorer/license/
91 schema:sdPublisher N7c45ea83d1a3438bbd12953bc77b574a
92 schema:url https://doi.org/10.1007/bf00116621
93 sgo:license sg:explorer/license/
94 sgo:sdDataset articles
95 rdf:type schema:ScholarlyArticle
96 N063c5592b08a4431b5426a4772f2d446 schema:name pubmed_id
97 schema:value 3470164
98 rdf:type schema:PropertyValue
99 N361abf7254d549eb9dcdbb5b44b5ac37 schema:issueNumber 1
100 rdf:type schema:PublicationIssue
101 N3b763161c85a4de9a090f180b667c15a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
102 schema:name Neoplasm Metastasis
103 rdf:type schema:DefinedTerm
104 N5de6c0fe657441fa8d79a6858129b44a schema:name doi
105 schema:value 10.1007/bf00116621
106 rdf:type schema:PropertyValue
107 N642bdffe351c406c8e932d74157b8984 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
108 schema:name Prognosis
109 rdf:type schema:DefinedTerm
110 N688293c2cd544b49ac35838b6aff492c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
111 schema:name Animals
112 rdf:type schema:DefinedTerm
113 N6a4ca3af41f64d55ab1aaea70b393e7b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
114 schema:name Rats
115 rdf:type schema:DefinedTerm
116 N6f13f0d15e074cb1a7827e492615f778 rdf:first sg:person.01041422577.30
117 rdf:rest Nfbe250fc6c96448bb33497df5a6be1fa
118 N71643238e24d4e89bc14baba149a8c9d schema:volumeNumber 5
119 rdf:type schema:PublicationVolume
120 N77bec66543ed40b6a2a096b15ae9eeb0 schema:name dimensions_id
121 schema:value pub.1008533853
122 rdf:type schema:PropertyValue
123 N7c45ea83d1a3438bbd12953bc77b574a schema:name Springer Nature - SN SciGraph project
124 rdf:type schema:Organization
125 N85603e679821435d8f46ceca4b19bf5a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
126 schema:name Neoplasm Transplantation
127 rdf:type schema:DefinedTerm
128 N954ea1a6ac064151b1b7ba6808ad7fea rdf:first sg:person.0763271342.13
129 rdf:rest N6f13f0d15e074cb1a7827e492615f778
130 Na0544e204a9249aeb8f87cee54baf279 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
131 schema:name Lung Neoplasms
132 rdf:type schema:DefinedTerm
133 Nc5b735afdd924d58868adf7900d85f3b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
134 schema:name Piperazines
135 rdf:type schema:DefinedTerm
136 Ne3cbb97a3aa34424a87312bfb085973d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
137 schema:name Razoxane
138 rdf:type schema:DefinedTerm
139 Nf25263e6f345401eae1c16dec74106a5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
140 schema:name Osteosarcoma
141 rdf:type schema:DefinedTerm
142 Nf6d6d1c7db7148c9bfde4ec55dcd0dd4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
143 schema:name Bone Neoplasms
144 rdf:type schema:DefinedTerm
145 Nfbe250fc6c96448bb33497df5a6be1fa rdf:first sg:person.0105462430.55
146 rdf:rest rdf:nil
147 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
148 schema:name Medical and Health Sciences
149 rdf:type schema:DefinedTerm
150 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
151 schema:name Clinical Sciences
152 rdf:type schema:DefinedTerm
153 sg:journal.1094856 schema:issn 0262-0898
154 1573-7276
155 schema:name Clinical & Experimental Metastasis
156 schema:publisher Springer Nature
157 rdf:type schema:Periodical
158 sg:person.01041422577.30 schema:affiliation grid-institutes:grid.7497.d
159 schema:familyName Spring
160 schema:givenName H.
161 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01041422577.30
162 rdf:type schema:Person
163 sg:person.0105462430.55 schema:affiliation grid-institutes:grid.7497.d
164 schema:familyName Schmähl
165 schema:givenName D.
166 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0105462430.55
167 rdf:type schema:Person
168 sg:person.0763271342.13 schema:affiliation grid-institutes:grid.7497.d
169 schema:familyName Wingen
170 schema:givenName F.
171 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0763271342.13
172 rdf:type schema:Person
173 sg:pub.10.1007/bf00116622 schema:sameAs https://app.dimensions.ai/details/publication/pub.1039110400
174 https://doi.org/10.1007/bf00116622
175 rdf:type schema:CreativeWork
176 sg:pub.10.1007/bf00254053 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013103800
177 https://doi.org/10.1007/bf00254053
178 rdf:type schema:CreativeWork
179 sg:pub.10.1038/222384a0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1049481269
180 https://doi.org/10.1038/222384a0
181 rdf:type schema:CreativeWork
182 grid-institutes:grid.7497.d schema:alternateName Institute of Experimental Pathology, German Cancer Research Centre, Im Neuenheimer Feld 280, 6900, Heidelberg, F.R. Germany
183 Institute of Toxicology and Chemotherapy, German Cancer Research Centre, Im Neuenheimer Feld 280, 6900, Heidelberg, F.R. Germany
184 schema:name Institute of Experimental Pathology, German Cancer Research Centre, Im Neuenheimer Feld 280, 6900, Heidelberg, F.R. Germany
185 Institute of Toxicology and Chemotherapy, German Cancer Research Centre, Im Neuenheimer Feld 280, 6900, Heidelberg, F.R. Germany
186 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...